Multiple Myeloma Clinical Trials in Denver, Colorado

20 studies are recruiting for multiple myeloma in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

   This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to pa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado

   Locations

   34 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04910568 on ClinicalTrials.gov

2. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, Denver, Colorado

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

3. A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

   This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM). The primary objective of this study is to evaluate the overall incidence of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, Denver, Colorado

   Locations

   6 in total

   Run by

   SCRI Development Innovations, LLC

   See if you can join NCT07637578 on ClinicalTrials.gov

4. A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

   The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste ch…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, Denver, Colorado

   Locations

   38 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06500884 on ClinicalTrials.gov

5. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, Denver, Colorado

   Locations

   144 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

6. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refr…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, Denver, Colorado

   Locations

   71 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07266441 on ClinicalTrials.gov

7. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, Denver, Colorado

   Locations

   151 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

8. A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in adult participants with relapsed/refractory (R/R) MM. Adverse events, to…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute /ID# 280275, Denver, Colorado

   Locations

   11 in total

   Run by

   AbbVie

   See if you can join NCT07409246 on ClinicalTrials.gov

9. A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

   The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, Denver, Colorado

   Locations

   16 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06768489 on ClinicalTrials.gov

10. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

    Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute /ID# 273129, Denver, Colorado

    Locations

    34 in total

    Run by

    AbbVie

    See if you can join NCT06892522 on ClinicalTrials.gov

11. Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

    The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    3 in total

    Run by

    Irene Ghobrial, MD

    See if you can join NCT05469893 on ClinicalTrials.gov

12. Selinexor and Backbone Treatments of Multiple Myeloma Patients

    This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    25 in total

    Run by

    Karyopharm Therapeutics Inc

    See if you can join NCT02343042 on ClinicalTrials.gov

13. A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

    This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Denver, Colorado

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07073547 on ClinicalTrials.gov

14. A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute /ID# 279080, Denver, Colorado

    Locations

    49 in total

    Run by

    AbbVie

    See if you can join NCT07095452 on ClinicalTrials.gov

15. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    212 in total

    Run by

    European Myeloma Network B.V.

    See if you can join NCT05243797 on ClinicalTrials.gov

16. Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

    This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patien…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    10 in total

    Run by

    University of Alabama at Birmingham

    See if you can join NCT05231629 on ClinicalTrials.gov

17. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

    This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute/SCRI, Denver, Colorado

    Locations

    32 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05828511 on ClinicalTrials.gov

18. Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adul…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute /ID# 273751, Denver, Colorado

    Locations

    27 in total

    Run by

    AbbVie

    See if you can join NCT06896916 on ClinicalTrials.gov

19. Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

    This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    17 in total

    Run by

    SCRI Development Innovations, LLC

    See if you can join NCT05972135 on ClinicalTrials.gov

20. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Colorado Blood Cancer Institute, Denver, Colorado

    Locations

    104 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov